JNJ

When Will Johnson & Johnson Post a Profit from its COVID Vaccine?

Johnson & Johnson (NYSE: JNJ) is selling its vaccine without taking a profit during the pandemic. In this Motley Fool Live video recorded on Feb. 26, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino talk about the potential duration of the pandemic and what that means for Johnson & Johnson.

10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of February 24, 2021

Corinne Cardina: Another thing that is obviously important for investors to know is that Johnson & Johnson, like AstraZeneca, has already agreed not to profit during the pandemic from this vaccine. Let's talk a little bit about when it could profit. Obviously, in the U.S., cases and deaths have decreased, a good 6% or maybe a little more of the U.S. population is vaccinated fully. Adria, when do you think we could move into a period when the pandemic is "over" and these companies could raise their prices to the point at which they can start profiting?

Adria Cimino: Well, if we go by Dr. Fauci, he said that the U.S. may reach some sense of normality by the end of the year. We can think of that and say, "Well, maybe by some point next year." Maybe midyear we could see an end to the pandemic, things really slowing down. I would think at the earliest, the idea of raising prices could come perhaps next year. The only thing with that is, I think by then the first round of vaccine will have gone out, so we can't expect immediately governments to be ordering tons and tons of doses. It might be more long term when we have to think of real profit for these companies. But I think in the long term it could be interesting because if it is every couple of years. And as a long-term investor we're looking at the revenue source years out, so I think this is something you want to keep in mind for the long term for these companies.

Adria Cimino has no position in any of the stocks mentioned. Corinne Cardina has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.